AML is an aggressive and mortal disease. Worldwide, approximately 120.000 new AML cases and over 100.000 AML-related deaths occur each year and FLT3 mutations contribute to poor prognosis in AML. FLT3 mutations of 149 patients aged 20-95 years who were diagnosed with AML in our clinic were evaluated retrospectively. Relapse/refractory disease was found in 87.2% of these cases and FLT3 mutation in 25.5%. Of mutation-positive cases 65.8% had FLT3-ITD mutation and 34.2% had FLT3-TKD mutation. In our study, 38 patients with newly diagnosed FLT3 mutations were treated with FLT3 inhibitors such as midostaurin, sorafenib, and sunitinib in combination with chemotherapy and 76.3% (n:29) of the patients with FLT3 mutation received midostaurin. Mortality rate was higher in those with FLT3-TKD mutation compared to those with FLT3-ITD mutation. The risk of mortality in patients who received midostaurin and chemotherapy was 2.0 times higher than the control group, which consisted mostly of relapsed/refractory patients who received only chemotherapy. The cumulative mortality rate in all patients was 66.4%, with a median OS of 44.8 months. Increasing age (HR: 1.03; p<0.001), presence of FLT3 mutation (HR: 1.82; p=0.007), presence of relapse/refractory disease (HR: 23.66; p=0.002) were associated with higher mortality. Mortality risk was low in patients with allogeneic stem cell transplantation (HR: 0.19; p<0.001). When the survival rate was analyzed according to FLT3 mutation, the presence of FLT3 mutation negatively affected survival (HR: 1.82). In conclusion, our study is important as it has the highest number of patients in the efficacy analysis of FLT3 inhibitors in our region, as far as we know. The prognostic impact of FLT3-TKD mutations remains mysterious due to the low frequency. Further studies recruiting more patients may be useful to better understand the efficacy of FLT3 inhibitors in patients with FLT3-TKD mutations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.